STAT+: Pharmalittle: We’re reading about Lilly bulking up on weight-loss drugs, scrutiny of a 340B contractor, and more
Stat News • 2/13/2026
Summary
Lilly is increasing its focus on weight-loss drugs, according to recent reports. Additionally, there is scrutiny surrounding a 340B contractor. This information is part of broader pharma news from the Pharmalot campus.
Advertisement
Lindy Score Breakdown (V4.2)
49d
Age
1
Sources
from cluster
1174
Hours Since Seen
Final Score0/100
CategoryAntiLindy
StatusArchived
Recency Multiplier0% (0.5^1174/48)
Hero EligibleNo
Score is 0 because recency decay (0.5^1174/48 = 0.000000) reduced it below 0.5
Score BreakdownRisk 50
Source Reputation: Low-trust source (4/20 pts)
Consensus: Single source - no independent confirmation yet
Age: 48 days - proven survivor
Stories gain Lindy status through source reputation, network consensus, and time survival.
Breaking Similar stories
STAT+: Pharmalittle: We’re reading about Trump tariff plans, FDA’s OK for a Lilly obesity pill, and more
Stat News • 1 day ago
STAT+: Pharmalittle: We’re reading about FDA view on peptide compounding, Iran war hurting trial recruitment, and more
Stat News • 2 days ago
STAT+: Trump announces 100% tariffs on brand-name drugs, with plenty of carveouts
Stat News • Today
STAT+: Trump administration prepares 100% tariffs on some imported drugs
Stat News • 1 day ago
STAT+: Baby KJ scientists hit speed bump in quest to scale custom gene editor
Stat News • 2 days ago
STAT+: FDA’s evolving view of what makes a ‘breakthrough’ device
Stat News • Today
STAT+: How health care could gum up Trump’s reconciliation push
Stat News • Today
STAT+: Can a psychedelic ‘coach’ make ketamine therapy even more effective?
Stat News • 2 days ago
STAT+: ‘Takeover Tuesday’ saves biotech’s quarter
Stat News • 1 day ago
STAT+: Proposed ‘preclinical obesity’ diagnosis ignites global debate among experts
Stat News • 1 day ago
Anti-Lindy Similar stories
STAT+: Pharmalittle: We’re reading about a Merck acquisition, the rise of former Loxo execs at Lilly, and more
Stat News • 1 week ago
STAT+: Pharmalittle: We’re reading about an FDA OK for a rare disease drug, a grilling of the PTO chief, and more
Stat News • 1 week ago
STAT+: Pharmalittle: We’re reading about Trump pushing drug pricing policy, Chinese biotech licensing, and more
Stat News • 4 days ago
STAT+: FDA approves Denali Therapeutics drug for Hunter syndrome
Stat News • 1 week ago